Notice to Creditors Regarding Objections to the Merger

SCAI Therapeutics Co., Ltd. (hereinafter referred to as the “Company” or “SCAI Therapeutics”) hereby announces that, in accordance with the small-scale merger procedure prescribed under Article 527-3 of the Korean Commercial Act, its Board of Directors, in place of a shareholders’ meeting, approved on November 29, 2024, the merger agreement with A-STIN Co., Ltd. (hereinafter referred to as “A-STIN”).

Under this merger, SCAI Therapeutics will be the surviving company and A-STIN will be dissolved. Accordingly, SCAI Therapeutics will succeed to all assets, liabilities, rights, and obligations of A-STIN.

Summary of the Merger

1. Overview:
   SCAI Therapeutics Co., Ltd. will absorb A-STIN Co., Ltd. Upon the completion of the merger, SCAI Therapeutics will continue as the surviving company, and A-STIN will be dissolved.

2. Scheduled Effective Date:
   December 31, 2024

3. Merger Ratio:
   1 : 10

Pursuant to Articles 527-5 and 232 of the Korean Commercial Act, SCAI Therapeutics hereby gives public notice to its creditors as follows:

[Notice to Creditors for Objection Submission]

1. Eligible Creditors:
   Creditors holding claims against SCAI Therapeutics Co., Ltd.

2. Objection Period:
   From November 29, 2024 to December 30, 2024 (one month)

3. Submission Address:
   Room A107, 17 Techno 4-ro, Yuseong-gu, Daejeon, Republic of Korea

4. Inquiries:

   • Department: Management & Administration Department

   • Tel: +82-42-867-0621

   • Email: kjkim@scaitrx.com

November 29, 2024
SCAI Therapeutics Co., Ltd.
Chief Executive Officer: Chul hwan Kim